

2-

[8].

GOLD [10],

[9].

(2,5 5),
()

[5].

2-5

2
a-1-

a-1-

a-1-

NICE

[11].

2

), : (,)
(,)
().

^
(,)
(,)
(,)

[12].

[6].

[7].

[2].

[25, 26].

5-15 /

[14].

2.

[15].

[7]

2

ARDS (

Levis J.F., 2003)

Alveofact		99% PL, 1% SP-B i SP-C	Boehringer Ingelheim, Ingelheim,
BLES*		75% oc a xo i i 1% SP-B a SP-C	BLES Biochemicals, London, Ontario,
Curosurf		, SP-B a SP-C (o e pa i ?)	Chiesti Farmaceutici, Parma,
CLSE**		, p a i , SP (B-290 / , C-300 /)	Forest Laboratories, New York, NY,
HL-10		?	Leo Pharma, Copenhagen,
Infasurf		, p a i , SP (B-290 / , C-300 /)	Forest Laboratories, New York, NY,
Surfaxin		, ^^	Discovery Labarotories, Doylestown, PA,
Survanta		, p a i SP (B<0,5%, C=99%)	Abbott Laboratories, Abbott Park, 2L,
Surfactant TA		, p a i SP (B<0,5%, C=99%)	Tokyo-Tanabe Co. LTD, Tokyo,
Venticute		c a e i o	Byk Pharmaceuticals, Constance,
op , po e c o y c a i			
ALEC***		70% , 30% oc a - i epo	Britannia Phrmaceuticals Limited, Redhill,
Exosurf		85% , 9% eca e a o , 0% o ca o	GlaxoSmithkline, Research triangle Park, NC,

: * BLEC — "Bovine Lipid Extract Surfactant"; ** CLSE—"Calflung Surfactant Extract"; *** ALEC — "Artificial Lung-Expanding Compound".

1. // - 2008. - 2. - 78-83.
2. // - 2003. - 57-60.
3. // - 2007. - 18. - 39-47.
4. // *Consilium Med.* - 2007. - 3. - 9. - 13-17.
5. / // - 200. - 2. - 39-41.
6. // - 2005. - 2. - 7. - 17-31.
7. // - 2008. - 1. - 33.
8. // - 2002. - 1. - C. 5-9.
9. // *Consilium Med.* - 2002. - 9. - T. 5. - C. 52-60.
10. - 2008. - 2. - 58-65.
11. Global Initiative for Chronic Obstructive Lung Disease (GOLD). *Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLB/WHO Workshop, 2003.* - 19 p.
12. Bittar G., HS Friedman. *The arrhythmogenicity of theophylline. A multivariate analysis of clinical determinants.* *Chest* 1991 Jun. 99(9): 1415-20.
13. Bames P.J. *Bronchodilators: basic pharmacology.* In Calvary P., Pride eds. *Chronic obstructive pulmonary disease.* London: Chapman and Hall, 1995: 391-417.
14. Global Initiative for Chronic Obstructive Lung Disease (based on the April 1998 NHLB/WHO Workshop). *National Institute of Health. National Heart Lung and Blood Institute. April 2001 (Updated 2003).*
15. MacInviere N.R. *Aerosolized medications for altering lung surface active properties* // *Respir Care.* 2004. - Vol. 45, 6. - P. 676-683.
16. Haistma J.J., Papadokos P.J., Lachman B. *Surfactant therapy for acute lung injury / acute respiratory distress syndrome.* // *Curr Opin Crit Care.* 2004. - 10(Feb). - P. 18-22.
17. Mora R., Arold S., Marzan Y. et al. *Determinants of surfactant function in acute lung injury and early recovery* // *Am. J. Physical. Lung. Cell. Mol. Physical.* - 2000. - Aug. Vol. 279, 2. - P. 342-9.
18. Dechert R.E. *The pathophysiology of acute respiratory distress syndrome* // *Respir. Care. Clin.* - 2003, Sep. - Vol. 9, 3. - P. 283-96.
19. Pelosi P., D'onofrio D., Chiumello D. et al. *Pulmonary and extrapulmonary acute respiratory distress syndrome are different* // *Eur. Respir. J. Suppl.* - 2003, Aug. Vol. 42-48. -S. 56S.
20. Callister M. E., Evans T. W. *Pulmonary versus extrapulmonary acute respiratory distress syndrome: different disease or just a useful concept* // *Curr. Opin. Crit. Care.* - 2002, Feb. - Vol. 8(1). - P. 25.
21. Lewis J.F., Brankenbury A. *Role of exogenous surfactant in acute lung injury.* // *Crit. Care. Med.* 2003, Apr. - Vol. 31(4 Suppl). - S. 324-328.
22. Clements J.A. *Surface tension of lung extracts* // *Proc. Soc Exp Bio Med.* 1957. - May, Vol. 95(1).P. 170-2.
23. Lewis J.F., Veldhuizen R. *The role of exogenous surfactant in the treatment of acute lung injury* // *Annual Review of Physiology.* - 2003, Vol. 65 (March). - P. 613-642.
24. Veldhuizen R.A., McCaig L.A., Akino T., Lewis J.F. *Pulmonary surfactant subfractions in patients with the acute respiratory distress syndrome* // *Am. J. Respir. Crit. Care Med.* - 1995, Dec. - Vol. 152 (6Pt1). P. 1867-1871.
25. Clark H., Reid K.B. *The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysema* // *Arch. Dis. Child.* - 2003, Nov. Vol. 88(11). - 981-984.
26. Clark H., Reid K. B. *Structural requirements for SP-D function in vitro and in vivo: therapeutic potential of recombinant SP-D* // *Immunobiol.* - 2002, Sep. - Vol. 208, 4-5. - P. 619-631.

19.04.2010

615.015.32:615.4531.07

A.V. Sheremeteva, S.A. Tichonova

PLACE OF SURFACTANT IN TREATMENT OF CHRONIC OBSTRUCTIVE PULMONAR DISEASE

Key words: surfactant, chronic obstructive pulmonary disease, anti-inflammatory activity

The clinical characteristics of chronic obstructive pulmonary disease and the medications based on surfactant have been performed in the review. Thus the theoretical background for research and development of a new drug for complex treatment of chronic obstructive pulmonary disease has been given.

616.311-008.87-07

*
1
1
1
2

1
2

() [8].
[15, 17].
()
[9], 90% — 0,5% — 20% 9,5%
[9, 19, 21]. 200).
()
Lactobacillus spp. Bifidobacterium spp.,
(, ,).
(-10)
[11].
1014